


INFORMATION DISCLOSURE CITATION 	Docket No.: RLL-256.1CIPUS	Serial No.: 10/520,572
	Applicants: MEHTA et al.	
	Filed: 1/19/2006	Group: 2183

SUPPLEMENTAL

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	S2A1	2006/0247225	11/2/2006	Mehta <i>et al.</i>	514	213.01	
	S2A2	2006/0287380	12/21/2006	Salman <i>et al.</i>	514	412	
	S2A3	2006/0281805	12/14/2006	Mehta <i>et al.</i>	514	412	
	S2A4	2007/0010568	1/11/2007	Mehta <i>et al.</i>	514	412	
	S2A5	2007/0135508	6/14/2007	Mehta <i>et al.</i>	514	412	
	S2A6	7,288,562	10/30/2007	Mehta <i>et al.</i>	514	412	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	S2C1	Wess <i>et al.</i> , "Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: A review", <i>Life Sciences</i> , <u>72</u> :2047-2054 (2003)
	S2C2	O'Neill, "Unusual suspect for antipsychotic-induced diabetes", <i>Drug Discovery Today</i> , <u>10</u> (20):1338 (2005)
	S2C3	Michel and Hegde, "Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?", <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , <u>374</u> :79-85 (2006)
	S2C4	Latifpour <i>et al.</i> , "Effects of Experimental Diabetes on Biochemical and Functional Characteristics of Bladder Muscarinic Receptors", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>248</u> (1):81-88 (1989)
	S2C5	Carrier and Aronstam, "Altered Muscarinic Receptor Properties and Function in the Heart in Diabetes", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>242</u> (2):531-535 (1987)
	S2C6	Ahrén <i>et al.</i> , "Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse", <i>Diabetologia</i> , <u>39</u> :383-390 (1996)
	S2C7	Abrams <i>et al.</i> , "Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder", <i>British Journal of Pharmacology</i> , <u>148</u> (5):565-578 (2006)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	